Shopping Cart (0)
My Account

 Shopping Cart
Conferences | Training Courses | Market Reports | Managed Events | Past Conferences | Update Me
SELECTBIO Conferences Antibody and Peptide Therapeutics
Conferences  \  BioProcessing, Biologics & Biotherapeutics Congress  \  Antibody and Peptide Therapeutics  \  Agenda  \  Melvyn Little
RegisterLogin

Melvyn Little's Biography


Melvyn Little, Chief Scientific Officer, Affimed Therapeutics AG

Sorry, There is currently no biography for this presenter.

Melvyn Little Image

A Tetravalent Bispecific Antibody (TandAb) for Treating Hodgkin´s Lymphoma – from Gene to Clinic

Wednesday, 20 July 2011 at 11:45

Add to Calendar ▼2011-07-20 11:45:002011-07-20 12:45:00Europe/LondonA Tetravalent Bispecific Antibody (TandAb) for Treating Hodgkin´s Lymphoma – from Gene to ClinicSELECTBIOenquiries@selectbiosciences.com

Immune effector cells are powerful killing agents. To harness them for treating tumors such as Hodgkin´s Lymphoma, we have developed a highly effective bispecific antibody format (TandAb). Product development from the gene to the clinic will be described.

Add to Calendar ▼2011-07-20 00:00:002011-07-21 00:00:00Europe/LondonAntibody and Peptide TherapeuticsSELECTBIOenquiries@selectbiosciences.com


Corporate Sponsors